Recent

% | $
Quotes you view appear here for quick access.

Catalyst Pharmaceuticals, Inc. Message Board

  • northerntrust@ymail.com northerntrust Nov 25, 2012 1:48 PM Flag

    Upgrade CPRX - Outperform

    On the ratings front, analysts at Rodman & Renshaw upgraded shares of Catalyst Pharmaceutical Partners from a “market perform” rating to an “outperform” rating in a research note to investors. They now have a $3.70 price target on the stock.

    Sentiment: Strong Buy

 
CPRX
1.25+0.14(+12.61%)Sep 23 4:00 PMEDT